Amyloid-β PET Imaging in Aging and Dementia

Amyloid-β imaging with positron emission tomography (PET) has been around since the early 2000s. It has transformed neuroimaging in Alzheimer’s disease (AD) by facilitating in vivo detection (and quantification) of amyloid-β plaques, one of the core pathological features of AD [1]. Initially, it was primarily used for research purposes and only infrequently in clinical practice. Now, more than a decade after the initial publications, it has become a standard diagnostic aid in specialised memory clinics.